Avidity Biosciences, Inc.
RNA
$25.48
-$1.09-4.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.99% | -0.19% | 8.15% | 12.50% | 3.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.99% | -0.19% | 8.15% | 12.50% | 3.64% |
| Cost of Revenue | 58.98% | 41.92% | 33.42% | 23.20% | 26.97% |
| Gross Profit | -61.35% | -44.37% | -34.93% | -23.84% | -28.49% |
| SG&A Expenses | 59.14% | 52.76% | 43.86% | 35.88% | 43.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.01% | 44.18% | 35.56% | 25.67% | 30.31% |
| Operating Income | -60.84% | -46.20% | -36.85% | -26.30% | -31.68% |
| Income Before Tax | -51.87% | -38.69% | -30.47% | -19.01% | -21.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.87% | -38.69% | -30.47% | -19.01% | -21.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.87% | -38.69% | -30.47% | -19.01% | -21.97% |
| EBIT | -60.84% | -46.20% | -36.85% | -26.30% | -31.68% |
| EBITDA | -61.10% | -46.24% | -36.75% | -26.05% | -31.53% |
| EPS Basic | 0.17% | 3.08% | 4.90% | 12.25% | 12.72% |
| Normalized Basic EPS | 0.17% | 3.08% | 4.91% | 12.26% | 12.73% |
| EPS Diluted | 0.17% | 3.08% | 4.90% | 12.25% | 12.73% |
| Normalized Diluted EPS | 0.17% | 3.08% | 4.91% | 12.26% | 12.73% |
| Average Basic Shares Outstanding | 52.76% | 44.05% | 36.52% | 33.82% | 40.01% |
| Average Diluted Shares Outstanding | 52.76% | 44.05% | 36.52% | 33.82% | 40.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
